Amazon cover image
Image from Amazon.com
Image from Google Jackets
Image from OpenLibrary

Advances in statistical bioinformatics : models and integrative inference for high-throughput data / edited by Kim-Anh Do, The University of Texas M.D. Anderson Cancer Center, Zhaohui Steven Qin, Emory University, Atlanta, GA, Marina Vannucci, Rice University, Houston, TX.

By: Contributor(s): Material type: TextTextPublication details: [Cambridge, England] : Cambridge University Press, c2013.Edition: 1st edDescription: xv, 481 pages : illustrations (some color)ISBN:
  • 9781107027527 (hardback)
Subject(s): DDC classification:
  • 572.802 DOK.A
Summary: "Chapter 1 An introduction to next-generation biological platforms Virginia Mohlere, Wenting Wang, and Ganiraju Manyam The University of Texas. MD Anderson Cancer Center 1.1 Introduction When Sanger and Coulson first described a reliable, efficient method for DNA sequencing in 1975 (Sanger and Coulson, 1975), they made possible the full sequencing of both genes and entire genomes. Although the method was resource-intensive, many institutions invested in the necessary equipment, and Sanger sequencing remained the standard for the next 30 years. Refinement of the process increased read lengths from around 25 to 2 Mohlere, Wang, and Manyam almost 750 base pairs (Schadt et al., 2010, fig. 1). While this greatly increased efficiency and reliability, the Sanger method still required not only large equipment but significant human investment, as the process requires the work of several people. This prompted researchers and companies such as Applied Biosystems to seek improved sequencing techniques and instruments. Starting in the late 2000s, new instruments came on the market that, although they actually decreased read length, lessened run time and could be operated more easily with fewer human resources (Schadt et al., 2010). Despite discoveries that have illuminated new therapeutic targets, clarified the role of specific mutations in clinical response, and yielded new methods for diagnosis and predicting prognosis (Chin et al., 2011), the initial promise of genomic data has largely remained so far unfulfilled. The difficulties are numerous"--
Tags from this library: No tags from this library for this title. Log in to add tags.
Holdings
Item type Current library Home library Call number Status Date due Barcode
Book Book IUCEIB Library, University of Kerala General Stacks IUCEIB Library, University of Kerala 572.802 DOK.A (Browse shelf(Opens below)) Available CEB245

This book describes the integration of high-throughput bioinformatics data from multiple platforms to inform our understanding of the functional consequences of genomic alterations.

Includes bibliographical references and index.

"Chapter 1 An introduction to next-generation biological platforms Virginia Mohlere, Wenting Wang, and Ganiraju Manyam The University of Texas. MD Anderson Cancer Center 1.1 Introduction When Sanger and Coulson first described a reliable, efficient method for DNA sequencing in 1975 (Sanger and Coulson, 1975), they made possible the full sequencing of both genes and entire genomes. Although the method was resource-intensive, many institutions invested in the necessary equipment, and Sanger sequencing remained the standard for the next 30 years. Refinement of the process increased read lengths from around 25 to 2 Mohlere, Wang, and Manyam almost 750 base pairs (Schadt et al., 2010, fig. 1). While this greatly increased efficiency and reliability, the Sanger method still required not only large equipment but significant human investment, as the process requires the work of several people. This prompted researchers and companies such as Applied Biosystems to seek improved sequencing techniques and instruments. Starting in the late 2000s, new instruments came on the market that, although they actually decreased read length, lessened run time and could be operated more easily with fewer human resources (Schadt et al., 2010). Despite discoveries that have illuminated new therapeutic targets, clarified the role of specific mutations in clinical response, and yielded new methods for diagnosis and predicting prognosis (Chin et al., 2011), the initial promise of genomic data has largely remained so far unfulfilled. The difficulties are numerous"--

There are no comments on this title.

to post a comment.